Philip Morris Rebuts 'Cynical' Claims About £1bn Vectura Buy
Tobacco Giant Moving Into Pharma
Buying the UK inhalation specialist Vectura will be key to the transformation of Philip Morris International as it looks to reduce its reliance on smoking products, CEO Jacek Olczak has declared.
You may also be interested in...
Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.
In this week's podcast edition of Five Must-Know Things: pharma’s Q2 prospects; Bayer’s plans for the US launch of its CKD drug; big tobacco takes further steps into healthcare; KRAS’s emergence in oncology amid ongoing challenges; and tips for European biotech fundraising.
Cash-rich private equity firms are eyeing opportunities in healthcare, especially among listed companies with sluggish share prices. The Carlyle Group could be getting a bargain if it seals a deal for the Chippenham-based inhalation specialist.